Introduction
The intestine is the largest surface of the body that is exposed to the external environment. Vast arrays of resident microbes colonize the human intestine to form the intestinal microbiota (or microflora). This is estimated to consist of up to 100 trillion microbial cells and constitutes one of the most densely populated bacterial habitats known in biology [1] [2] [3] . In the GIT bacteria colonize an intestinal niche where they survive and multiply 4 . In return, the microbiota endows the host with additional functional features not encoded on its genome 1 . For example the microbiota stimulates the proliferation of epithelial cells, produces vitamins that hosts cannot produce by themselves, regulates metabolism and protects against pathogens [4] [5] [6] . Given this beneficial relationship, some authors have suggested that humans are "super-organisms" or "holobionts" that are a mix of bacterial and human genes 7, 8 . Given the beneficial impact of the microbiota on the (human) host, the intestinal immune system needs to tolerate commensal microbes to enable their existence in the lumen but also kill the pathogens that invade from luminal side [9] [10] [11] . The intestinal immune system has developed mechanisms to distinguish between harmless and potentially harmful luminal microbes; however these mechanisms are not yet well understood 12 . Maintaining intestinal integrity requires a tightly regulated immune homeostasis to keep the balance between tolerance and immunity 13 . An imbalance in immune homeostasis contributes to the induction of intestinal diseases such as inflammatory bowel disease (IBD) 3, 14 .
There are two major types of IBD: Crohn's disease (CD) and ulcerative colitis (UC). Patients with these diseases usually suffer from rectal bleeding, severe diarrhea and abdominal pain 15, 16 . The single cause of IBD is still unknown, but a combination of genetic factors, environmental influences and dysregulated immune responses might be the key event for disease development 15 .
Animal models for IBD have been used for over 50 years. In the last few decades new IBD model systems have been developed to test the various hypotheses concerning the pathogenesis of IBD 17, 18 . The best-characterized model of chronic colitis is the T-cell transfer model that induces disruption of T-cell homeostasis 19, 20 . This model involves transferring naive T cells from immunocompetent mice into hosts that lack T and B-cells (such as RAG -/-and SCID mice) 16, 21 . The development of disease in this model is monitored for 3-10 weeks by evaluating the presence of diarrhea, reduced physical activity, and loss of body weight. This is so called the wasting syndrome 16 . Compared to the healthy mice the colonic tissue of transplanted hosts is thicker, shorter and heavier . Although many aspects of IBD have been clarified, the initial events that lead to the disease development still need to be clearly understood.
It has been shown that in the absence of microbiota transfer colitis cannot be established 24 . Recently, several theories suggest that IBD could be a result of an immune response against commensal bacteria 25 . Authors have also proposed that commensal bacteria are essential to induce inflammation in the distal intestine 26 . In germ free (GF) animals the intestinal immune system is generally impaired 27, 28 , but a colonization of these mice with a mixture of specific-pathogen-free bacteria results in the development of the fully-competent intestinal immune system 29 . Hence, the microbiota seems to be a key element in the pathogenesis of IBD, either as a mechanism that predisposes to or protects against the development of intestinal inflammation 30, 31 . Current theories suggest that IBD is a result of microbial imbalance, called dysbiosis, in genetically predisposed patients 32 , but it is not clear yet if the dysbiosis is the cause or the consequence of the disease 12 . Considering the role of microorganisms in the development of IBD, in vitro experiments showed that CD4 + T cells can be activated by APCs pulsed with intestinal bacteria 33, 34 .
Moreover, it has been shown that antigens from different commensal bacterial species, such as E. coli, Bacteroides, Eubacterium and Proteus, are able to activate CD4 + T cells 35 . This indicates that presentation of bacterial antigens to T cells is of importance for the development of IBD. To reduce the complexity of multiple antigens derived by the microflora in the disease process, an E.coli strain has been created that produces the OVA antigen. Transfer colitis was induced by injecting OVA-specific T cells into RAG -/-animals colonized with OVA-expressing E. coli.
This model is based on recent evidence suggesting that CX 3 CR1 + MPs, a major cell subset in the colonic lamina propria (cLP) 36 , are interacting with CD4 + T cells during transfer colitis 37 . MPs sample the intestinal lumen for particulate antigen, such as bacteria, using their dendrites 36, 38, 39 . Previous studies demonstrated that MPs can also take up soluble antigens, such as OVA, introduced into the intestinal lumen 40, 41 . 
Protocol
Mice were bred and kept under specific pathogen-free (SPF) conditions in the animal facility of Ulm University (Ulm, Germany). All animal experiments were performed according to the guidelines of the local animal use and care committee and the National Animal Welfare Law.
Construction of the pCFP-OVA Plasmid
1. Amplify the full size OVA gene using the primers Ova_SpeI_fw (3'-GACCAACTAGTATGGAATTTTGTTTTGATGTATT-5') and Ova_ClaI_rev (3'-GACCAGATCGATTAAGGGGAAACACATCTGCC-5') 37 using plasmid pCI-OVA (ampicillin resistant) 42 as a template. Clone the PCR product (i.e. the OVA coding sequence) into a commercially available phage mid-vector using SpeI and ClaI restrictions sites of the primers and vector to yield the specific OVA-plasmid. 2. Amplify the CFP-coding gene together with the strong constitutive promoter P hyper using plasmid pAD 1 -cCFP (chloramphenicol resistant) 43 as a template and primers CFP_SacII_fw (3'-GATCGACCGCGGTTCTTGAAGACGAAAGGGCC-5') and CFP_SpeI_rev (3'-GATCGAACTAGTACCACCACCACCACCACCTTTGTAGAGTTCATCCATGC-5') 37 . 3. Clone the CFP-coding gene into the specific OVA-plasmid (ampicillin resistant) using the SpeI and SacI restriction sites of the primers and vector 37 . This introduces a spacer of 6 glycine residues between the CFP-coding from OVA-coding sequence.
Construction of E.coli pCFP-OVA
1. Grow E.coli strain DH10B in 100 ml of Luria Bertani (LB) medium aerobically at 37 °C on a rotary shaker overnight. 2. Mix 800 µl of bacterial culture with 200 µl of glycerol to create glycerol stock and store at -80 °C. 3. Add 50 µl of E.coli strain DH10B from glycerol stock in 5 ml of LB medium and grow them aerobically at 37 °C on a rotary shaker overnight. 4. Transfer the culture in a baffled 1 L Erlenmeyer flask with 250 ml of LB medium at 37 °C in a rotary shake. 5. Grow bacteria to an optical density at 600 nm (OD 600 ) of 0.5 and then chill the culture on ice for 30 min. Centrifuge the bacteria at 5,000 x g for 10 min at 4 °C. 6. Resuspend bacteria with 100 ml of ice-cold sterile H 2 O and centrifuge the bacteria at 5,000 x g for 10 min at 4° C. Resuspend bacteria with 100 ml of ice-cold 10% glycerol and centrifuge the bacteria at 5,000 x g for 10 min at 4 °C. Repeat this last step twice. 7. After the final wash step, resuspend bacteria in 700 µl of 10% glycerol. Freeze 50 µl aliquots in liquid nitrogen and store at -80 °C. 8. Thaw a 50 µl aliquot on ice and transfer into a pre-chilled electroporation cuvette (2 mm electrode distance). 9. Add 5 µl of plasmid DNA (100 ng) to the 50 µl E. coli aliquots. Perform electroporation with a single pulse at 25 µF, 200 ohms (Ω) and 2.5 kV. 10. Resuspend bacteria in 1 ml pre-warmed SOC medium (5 g/L yeast extract, 2 g/L tryptone, 10 mM sodium chloride, 2.5 mM potassium chloride, 10 mM magnesium chloride, 10 mM magnesium sulfate) and incubate at 37 °C aerobically for 1 hr. 11. Plate bacteria on LB-agar plates supplemented with ampicillin 100 µg/ml (add 100 µl of a 100 mg/ml ampicillin stock to 100 ml of LB-agar) and incubate overnight aerobically at 37 °C. 12. Pick single colonies and re-streak them in LB-agar plates supplemented with ampicillin 100 µg/ml. Incubate overnight aerobically at 37 °C. 13. Pick single colonies and grow them overnight in 10 ml of LB media supplemented with ampicillin 100 µg/ml for plasmid isolation. Use commercially available plasmid mini prep kit and elute plasmid DNA with 30 µl dH 2 O (distilled water) according to manufacturer's protocol. Verify plasmids by restriction analysis and DNA sequencing 37, 42, 43 . 14. Set up a culture of positive clones of E. coli pCFP-OVA in 100 ml of LB medium supplemented with ampicillin 100 µg/ml. Grow aerobically at 37 °C on a rotary shaker overnight. 15. Mix 800 µl of bacterial culture with 200 µl of pure glycerol and store at -80 °C. 16 . Centrifuge the rest of the overnight culture at 5,000 x g for 10 min at room temperature (RT) and resuspend the pellet in phosphate buffered saline (PBS). Place 10 µl of the suspension onto glass slide and cover it with a coverslip. 17. Observe the samples in a standard fluorescence microscopy to confirm the expression fluorescence of CFP-OVA (CFP excitation at 450 nm, emission at 480 nm). Analyze the bacteria starting with magnification 400X. 18. Centrifuge 1 ml of bacteria from overnight cultures at 5,000 x g for 10 min, RT. Resuspend the pellet in 40 µl of PBS and boil at 95 °C for 10 min. 19. Centrifuge the samples at 30,000 x g for 10 min and use the supernatants for Western blot analysis 37 . Use the rabbit-raised anti-OVA polyclonal antibody diluted 1:400.
Generation of OT-II/Red Mice
1. Cross a male/female OT-II mouse with a female/male mouse expressing red fluorescent protein (both strains commercially available) in order to generate the OT-II/Red mice 37 .
Spleen Cell Isolation
1. Euthanize the OT-II/Red mice by cervical dislocation after anesthesia by inhalation of any halogenated ether (up to 5% for induction) commercially available. 2. Use scissors to cut the left superior abdominal part of the mouse. Under this abdominal part there is the spleen (oval shape with a dark-red color). Use scissors and tweezers to remove it. 1. Extract the spleen of the OT-II/Red mice and pass it through a 100 µm cell strainer positioned on a 50 ml tube using the plunger of a 1 ml syringe in order to obtain a single-cell suspension. Wash the strainer twice with 10 ml of PBS supplemented with 1% heat inactivated fetal bovine serum (FBS). NOTE: In the negative selection procedure, the cells, which will be not isolated (here: all CD4 negative cells) are labeled with specific antibodies coupled with magnetic microbeads. During the column washing steps the CD4 + T cells will pass through the column so that they can be easily collected. In the positive selection procedure cells to be isolated are labeled with appropriate antibody coupled with magnetic microbeads. During the column washing steps the labeled cells will stay in the column and they can be collected by removing the column from the magnetic field and rinsing it with the buffer. 1. Add to the sample 10 ml of PBS supplemented with 0.5% BSA and centrifuge at 390 x g for 5 min. Repeat this step twice. Resuspend in 500 µl of cold PBS supplemented with 0.5% BSA.
2. Place the specific column for the negative selection procedure in the magnetic field and rinse with 500 µl of cold PBS supplemented with 0.5% BSA onto the column. Add cell suspension onto the column and wash 3 times with 500 µl of cold PBS supplemented with 0.5% BSA. 3. Remove the column from the magnetic field and place it on a suitable collection tube. Add 1 ml of PBS supplemented with 0.5% BSA onto the column and flush out CD4 + CD62L + T cells retained in the column by firmly pushing the plunger into the column. 
Tissue Samples for Histopathological Examination
1. Take tissue samples from the large intestine of mice, fix in neutral-buffered formalin (10%) and embed in paraffin as previously described 36, 46 . 2. Section the paraffin samples on a microtome, mount on slides, and perform the H&E stain 47, 48 . 3. Categorize the histology of the large intestine as published previously 47, 48 : normal (score 0); mild colitis (score 1), moderate colitis (score 2) and severe colitis (score 3).
Isolation of Colonic Lamina Propria Cells
1. Euthanize transplanted mice by cervical dislocation after anesthesia by inhalation of any halogenated ether (up to 5% for induction) commercially available. 2. Place the animal down with the belly facing up. Use forceps to grab the skin anteriorly to the urethral opening. Use scissors to cut the skin along the ventral midline from the groin to the chest. Pull the skin back on the sides. 3. Cut through the transparent peritoneal muscle wall and opening up the body cavity. Identify the colon that goes from the anus to the caecum 49 . Cut the 2 extremities and free the tissue from any fat. 4. Open the colon longitudinally using a dissection scissors. Use a tweezers to shake the colon tissue in a petri dish containing 25 ml of PBS supplemented with 1% FBS to remove debris and mucous. Cut the colon into 5 -8 mm pieces. 5. Place the colon segments in a 50 ml tube containing 20 ml of the Wash Buffer. The Wash buffer contains 500 ml DPBS, 10mM Hepes and 5mM ethylenediaminetetraacetic acid (EDTA). 6. Vortex the tube for 30 sec at maximal speed. 7. Incubate the tube with the colon segments in a water bath at 37 °C with 200 rpm shaking for 10 min. 8. After the incubation, vortex the tube for 30 sec at maximal speed. 9. Discard the supernatants and place the tissue samples in a new 50 ml tube containing 20 ml of the Wash buffer. Repeat steps 6-9 three times 10. Discard the supernatants and place the tissue samples in a petri dish containing 25 ml of PBS. Use a tweezers to shake gently the tissue samples in the petri dish for few seconds to remove residual epithelial cells. Repeat this step three times. 11. Cut colonic tissues into 2 x 2 mm 2 pieces and digest them by incubation in 10 ml of Roswell Park Memorial Institute (RPMI) medium with 0.5 mg/ml collagenase type VIII from Clostridium histolyticum and 10 U/ml of DNaseI. 12. Vortex the tube for 30 sec at maximal speed. CFU of E. coli strain DH10B pCFP-OVA. 2. Remove the colon from the mice using scissors and tweezers. Open it longitudinally using a dissection scissors. 3. Cut a 5-8 mm piece of colon sample using scissors, put onto glass slides and cover with coverslips. 4. Analyze the colon samples with a confocal microscope at a magnification of 40/1.30.
Detect the CX 3 CR1
+ MPs, labeled with green fluorescein protein (GFP), using a filter set with excitation at 488 nm and emission at 509 nm.
6. Detect the CD4 + T cell expressing red protein using a filter set with excitation at 554 nm and emission at 586 nm.
7. Detect E.coli pCFP-OVA using a filter set with excitation at 450 nm and emission at 480 nm. 8. Define an area of interest and generate scatter diagrams as previously described 50 to carry out the co-localization analysis. Use 2 different formulas: the Overlap Coefficient according to Manders and the Pearson's Coefficient.
Representative Results
To establish an antigen-driven colitis model an E. coli strain has been constructed that contains a plasmid in which the gene for the CFP is fused to the coding sequence for the chicken ovalbumin protein and the fusion construct is expressed under control of the strong constitutive promoter P hyper ( Figure 1A) . Fluorescent microscopy shows that the recombinant E. coli pCFP-OVA, but not the parental E. coli DH10B, expresses CFP ( Figure 1B) . CFP-OVA-producing E. coli is able to activate OT-II cells in vitro and induce IFN-γ production in contrast to an E. coli strain expressing CFP only (Figure 2) . Figure 3A shows ex vivo 3D confocal imaging of the colonic tissue of CX 3 CR1 GFP/+ mice fed with E. coli pCFP-OVA. E. coli pCFP-OVA can be detected within colonic crypts located close to intestinal epithelial cells and co-localizes with CX 3 CR1 + phagocytes. To determine the relative proportion of E. coli pCFP-OVA internalized by defined CX 3 CR1 + phagocytes, the blue and green florescence intensity were determined by scatter blots. The analysis revealed that CX 3 CR1 + cells sampled 11.9 ± 1.5% of E. coli pCFP- 
Discussion
As with every other model, the antigen-driven colitis model described above may present few issues that the investigator performing the technique must be aware of. When injecting the OT-II/Red + CD4 + T CD62L + cells in the hosts, the investigator must be very gentle and careful to insert the needle into the peritoneal cavity. Failure to do so may result in the tearing of the intestine of the mouse which could lead to death, or a subcutaneous administration of cells which will not induce any disease.
Typically, mice will gain weight during the first week after cell transfer. The investigator should weigh the mice at the same time at each weight time point and use the same weighing balance throughout the whole procedure. Sometimes the experimental mice, especially when their weight at the beginning of the experiment is below 18 g, do not develop any signs of the wasting syndrome. However, these animals might still develop significant intestinal inflammation under macroscopic evaluation.
When working with genetically modified bacteria, contaminations can occur. To avoid these issues it is highly recommended to check the E.coli expressing CFP-OVA using the fluorescent microscope to analyze if the bacteria are fluorescent and are rod-shaped (the typical E.coli shape).
The proposed antigen driven-colitis relies on the observation that CX 3 CR1 + MPs sample commensal luminal bacteria in the steady state and during inflammatory conditions 36, 37 . . This is consistent with previous studies in which, after adoptive transfer of OT-II T cells in RAG -/-mice, colitis was only induced when the hosts were challenged with OVA-expressing E. coli 51 .
Confocal imaging suggests that CX 3 CR1 + phagocytes are located close to the intestinal epithelium so that they can sample E. coli pCFP- 37, 52 . Primed T cells assemble in the cLP where CX 3 CR1 + phagocytes show the OVA antigen to effector T cells to induce inflammation. The delivery and presentation of the antigen by CX 3 CR1 + phagocytes could be a key event in the development of colitis.
The ability to induce colitis with a defined bacterium expressing a specific antigen provides the opportunity to study the necessary conditions for the development of colitis 24 . This model shows that a specific response to an antigenic peptide (OVA expressed by E. coli) is sufficient to induce intestinal inflammation in RAG -/-hosts, suggesting that T cells may react to specific antigen from the intestinal microflora. A single antigen can induce intestinal inflammation in the animal models but it cannot be assumed that single antigens are the cause of human IBD. Moreover, in the transfer colitis model there are naive CD4 + T cells that have unknown specificity and therefore may be reactive to multiple,
as of yet unidentified antigens, from the microbiota. Major analysis and studies are needed to better clarify the role of a specific antigen in the pathogenesis of mucosal inflammation.
In recent years the usage of different animal model of colitis has led to an expansion in the knowledge of the pathogenesis of IBD 53 . However, due to the complexity and to the pathogenesis of the disease, there is not a definitive cure 54 . Using the described model, it is possible to address several aspects of IBD that are not well clarified yet, such as (i) interactions between monocytes and dendritic cells, (ii) migration of intestinal DCs to the MLN, (iii) antigen presentation, (iv) homing of effector T cells from MLN to the lamina propria and (v) activation of effector T cells in the lamina propria by CX 3 CR1 + phagocytes. However, further studies are needed to confirm if the CX 3 CR1 + phagocyte/CD4 + T cell interaction plays a key role in the IBD pathogenesis. Mice cannot be truly representative of humans and this must be kept in mind when mouse models are used to study human IBD 2 .
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